Conv. Plasma
Nigella Sativa

All regdanvimab studies
Meta analysis
study COVID-19 treatment researchRegdanvimabRegdanvimab (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Oxygen therapy 60% Improvement Relative Risk Discharge, day 14 44% Discharge, day 11 35% Hospitalization time 13% Regdanvimab for COVID-19  Jang et al.  EARLY TREATMENT Is early treatment with regdanvimab beneficial for COVID-19? Retrospective 210 patients in South Korea (September 2020 - July 2021) Lower need for oxygen therapy (p<0.0001) and higher discharge (p=0.025) Jang et al., Current Therapeutic Resea.., May 2022 Favors regdanvimab Favors control

Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study

Jang et al., Current Therapeutic Research, doi:10.1016/j.curtheres.2022.100675
May 2022  
  Source   PDF   All   Meta
35th treatment shown to reduce risk in March 2022
*, now known with p = 0.0000009 from 7 studies, recognized in 27 countries. Efficacy is variant dependent.
Lower risk for hospitalization, progression, and recovery.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Retrospective 317 hospitalized mild-moderate COVID-19 patients in South Korea showing significantly lower rates of oxygen desaturation (SpO2 <94%) at 28 days (primary outcome) with regdanvimab monoclonal antibody treatment (13%) compared to standard of care (40%). Regdanvimab also showed benefits in time to fever recovery, discharge rates, and supplemental oxygen use.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2, BA.4, BA.5 Haars, ХВВ.1.9.1, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.1 Pochtovyi.
risk of oxygen therapy, 59.6% lower, RR 0.40, p < 0.001, treatment 17 of 73 (23.3%), control 79 of 137 (57.7%), NNT 2.9.
risk of no hospital discharge, 44.1% lower, RR 0.56, p = 0.03, treatment 14 of 73 (19.2%), control 47 of 137 (34.3%), NNT 6.6, day 14.
risk of no hospital discharge, 34.9% lower, RR 0.65, p < 0.001, treatment 34 of 73 (46.6%), control 98 of 137 (71.5%), NNT 4.0, day 11.
hospitalization time, 12.9% lower, relative time 0.87, p = 0.003, treatment mean 12.1 (±4.0) n=73, control mean 13.9 (±4.3) n=137.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Jang et al., 16 May 2022, retrospective, South Korea, peer-reviewed, 3 authors, study period September 2020 - July 2021. Contact:
This PaperRegdanvimabAll
Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study
MD Young Rock Jang, MD Yoon Ju Oh, MD, MPH Jin Yong Kim
Current Therapeutic Research, doi:10.1016/j.curtheres.2022.100675
Background: In a Phase III study, regdanvimab (CT-P59) reduced the risk of hospitalization or death versus placebo in patients with mild-to-moderate coronavirus disease 2019 (COVID-19). Purpose: We performed a retrospective cohort study of patients with COVID-19 to examine the effect of regdanvimab versus standard of care (SoC) on oxygen saturation. Methods: We reviewed patients with mild-to-moderate COVID-19 confirmed by reverse transcriptionpolymerase chain reaction at a single hospital in the Republic of Korea. The primary efficacy end point was the proportion of patients deteriorating with peripheral capillary oxygen saturation < 94% on room air up to day 28. Results: A total of 127 patients were treated for COVID-19 with regdanvimab, 190 with SoC. The proportion of patients deteriorating with peripheral capillary oxygen saturation < 94% on room air up to day 28 was 13.4% with regdanvimab and 39.5% with SoC ( P < 0.0 0 01); median time (range) until sustained recovery of fever was 2.0 (0.2-14.8) and 4.2 (0.1-17.1) days, respectively. Supplemental oxygen was required by 23.6% of patients with regdanvimab and 52.1% with SoC ( P < 0.0 0 01) for a mean of 6.3 and 8.7 days, respectively ( P = 0.0113); no patients needed mechanical ventilation. Compared with SoC, hospitalization was shorter with regdanvimab (mean = 11.1 vs 13.6 days; 63.8% vs 31.6% discharged within 11 days; both P values < 0.0 0 01). Fewer regdanvimab-treated patients required remdesivir (14.2% vs 43.2%; P < 0.0 0 01). There were no deaths. Two patients had adverse reactions with regdanvimab. Conclusions: This real-world study indicates that regdanvimab can prevent deterioration in patients with mild-to-moderate COVID-19. (
Conflicts of Interest Statement The authors have indicated that they have no conflicts of interest regarding the content of this article.
Alam, Mahmud, Aggarwal, Clinical impact of the early use of monoclonal antibody LY-CoV555 (bamlanivimab) on mortality and hospitalization among elderly nursing home patients: a multicenter retrospective study, Cureus
Baraniuk, Where are we with drug treatments for covid-19?, BMJ
Berlin, Gulick, Martinez, Severe Covid-19, N Engl J Med
Bierle, Ganesh, Wilker, Influence of social and cultural factors on the decision to consent for monoclonal antibody treatment among high--risk patients with mild-moderate COVID-19, J Prim Care Community Health
Brouqui, Amrane, Million, Asymptomatic hypoxia in COVID-19 is associated with poor outcome, Int J Infect Dis
Chen, Feng, Xu, Patterns of deterioration in moderate patients with COVID-19 from Jan 2020 to Mar 2020: a multi-center, retrospective cohort study in China, Front Med
Corti, Purcell, Snell, Veesler, Tackling COVID-19 with neutralizing monoclonal antibodies, Cell
Gottlieb, Nirula, Chen, Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA
Gupta, Marks, Samuels, Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study, Eur Respir J
Kim, Jang, Hong, Safety, virologic efficacy, and pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against SARS-CoV-2 spike receptor-binding protein: two randomized, placebo-controlled, phase I studies in healthy individuals and patients with mild SARS-CoV-2 infection, Clin Ther
Kumar, Wu, Stosor, Real-world experience of bamlanivimab for COVID-19: a case-control study, Clin Infect Dis
Marston, Paules, Fauci, Monoclonal antibodies for emerging infectious diseases -borrowing from history, N Engl J Med
Rechtman, Curtin, Navarro, Nirenberg, Horton, Vital signs assessed in initial clinical encounters predict COVID-19 mortality in an NYC hospital system, Sci Rep
Ryu, Kang, Noh, The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2, Biochem Biophys Res Commun
Ryu, Song, Kim, Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant, Biochem Biophys Res Commun
Sandulsecu, Therapeutic effect of regdanvimab in patients with mild to moderate COVID-19: day 28 results from a multi-centre, randomised, controlled pivotal trial
Sanitária -Anvisa, Anvisa autoriza uso emergencial de novo medicamento para Covid-19
Syed, Regdanvimab: First Approval, Drugs
Venkatesan, Repurposing drugs for treatment of COVID-19, Lancet Respir Med
Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med
Wouters, Shadlen, Salcher-Konrad, Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment, Lancet
Zhai, Luo, Zheng, Moderate vs. mild cases of overseas-imported COVID-19 in Beijing: a retrospective cohort study, Sci Rep
Zhang, Wang, Zhao, The clinical characteristics and prognosis factors of mild-moderate patients with COVID-19 in a mobile cabin hospital: a retrospective, single-center study, Front Public Health
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop